LYEL
Price
$2.74
Change
-$0.05 (-1.79%)
Updated
May 17, 6:59 PM EST
82 days until earnings call
RLAY
Price
$6.63
Change
+$0.10 (+1.53%)
Updated
May 17, 6:59 PM EST
82 days until earnings call
Ad is loading...

LYEL vs RLAY

Header iconLYEL vs RLAY Comparison
Open Charts LYEL vs RLAYBanner chart's image
Lyell Immunopharma
Price$2.74
Change-$0.05 (-1.79%)
Volume$885.75K
CapitalizationN/A
Relay Therapeutics
Price$6.63
Change+$0.10 (+1.53%)
Volume$1.19M
CapitalizationN/A
View a ticker or compare two or three
LYEL vs RLAY Comparison Chart

Loading...

LYELDaily Signal changed days agoGain/Loss if shorted
 
Show more...
RLAYDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
LYEL vs. RLAY commentary
May 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LYEL is a StrongBuy and RLAY is a Hold.

COMPARISON
Comparison
May 18, 2024
Stock price -- (LYEL: $2.78 vs. RLAY: $6.51)
Brand notoriety: LYEL and RLAY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LYEL: 75% vs. RLAY: 104%
Market capitalization -- LYEL: $698.53M vs. RLAY: $881.4M
LYEL [@Biotechnology] is valued at $698.53M. RLAY’s [@Biotechnology] market capitalization is $881.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $593.52B to $0. The average market capitalization across the [@Biotechnology] industry is $2.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LYEL’s FA Score shows that 0 FA rating(s) are green whileRLAY’s FA Score has 1 green FA rating(s).

  • LYEL’s FA Score: 0 green, 5 red.
  • RLAY’s FA Score: 1 green, 4 red.
According to our system of comparison, RLAY is a better buy in the long-term than LYEL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LYEL’s TA Score shows that 6 TA indicator(s) are bullish while RLAY’s TA Score has 4 bullish TA indicator(s).

  • LYEL’s TA Score: 6 bullish, 4 bearish.
  • RLAY’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, LYEL is a better buy in the short-term than RLAY.

Price Growth

LYEL (@Biotechnology) experienced а +3.73% price change this week, while RLAY (@Biotechnology) price change was +3.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.81%. For the same industry, the average monthly price growth was +4.40%, and the average quarterly price growth was +61.33%.

Reported Earning Dates

LYEL is expected to report earnings on Aug 07, 2024.

RLAY is expected to report earnings on Aug 07, 2024.

Industries' Descriptions

@Biotechnology (+2.81% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for LYEL with price predictions.
OPEN
A.I.dvisor published
a Summary for RLAY with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
RLAY($881M) has a higher market cap than LYEL($699M). LYEL YTD gains are higher at: 43.299 vs. RLAY (-40.872).
LYELRLAYLYEL / RLAY
Capitalization699M881M79%
EBITDAN/AN/A-
Gain YTD43.299-40.872-106%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
TECHNICAL ANALYSIS
Technical Analysis
LYELRLAY
RSI
ODDS (%)
Bearish Trend 3 days ago
73%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 16 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 9 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
View a ticker or compare two or three
Ad is loading...
LYELDaily Signal changed days agoGain/Loss if shorted
 
Show more...
RLAYDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BGLTX29.590.11
+0.36%
Baillie Gifford Long Term Global Gr 2
MEPAX13.70N/A
N/A
MassMutual Disciplined Value A
CGVHX23.08-0.04
-0.17%
American Funds Global Insight 529-F-3
AICGX35.68-0.12
-0.34%
American Century Discplnd Cor Val R5
GMRIX11.95-0.07
-0.58%
Nationwide Small Cap Index R6

LYEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, LYEL has been loosely correlated with NTLA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if LYEL jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYEL
1D Price
Change %
LYEL100%
+6.51%
NTLA - LYEL
51%
Loosely correlated
-0.19%
ADPT - LYEL
50%
Loosely correlated
-4.62%
NRIX - LYEL
46%
Loosely correlated
-3.14%
VCYT - LYEL
46%
Loosely correlated
-0.64%
RLAY - LYEL
43%
Loosely correlated
-4.19%
More

RLAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLAY has been loosely correlated with PRME. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if RLAY jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLAY
1D Price
Change %
RLAY100%
-4.19%
PRME - RLAY
53%
Loosely correlated
+4.14%
NTLA - RLAY
52%
Loosely correlated
-0.19%
ADPT - RLAY
48%
Loosely correlated
-4.62%
BEAM - RLAY
48%
Loosely correlated
-1.33%
RXRX - RLAY
47%
Loosely correlated
-5.00%
More